Biomarkers | Surviving Mesothelioma

Predicting Mesothelioma Outcomes with Soluble Mesothelin

New research suggests that a protein often used to help diagnose and track malignant mesothelioma may also be a valuable prognostic indicator. Soluble mesothelin-related protein (SMRP) is a biomarker for pleural mesothelioma, an aggressive asbestos-linked cancer that causes few symptoms until in its late stages. The presence of SMRP in the blood indicates that mesothelial cells on the lining around the lungs have been damaged. … Continue reading Predicting Mesothelioma Outcomes with Soluble Mesothelin »

More Evidence for Inflammation Marker in Mesothelioma Prognosis

There is more evidence that a measure of how well the immune system is functioning may be an efficient prognostic tool for people with malignant pleural mesothelioma. Even though some recent studies have found the ratio of neutrophils to lymphocytes (NLR) in the blood to be a poor prognostic indicator for cancer, Chinese researchers say it may still be effective for planning mesothelioma treatment and qualifying … Continue reading More Evidence for Inflammation Marker in Mesothelioma Prognosis »

Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers

Biologist Holding Flasks

A biomarker called soluble mesothelin related peptide (SMRP) may be a more reliable way to diagnose malignant pleural mesothelioma from lung fluid than the protein fibulin-3. That is the finding of Italian researchers who tested the diagnostic performance of the two markers in 120 patients, including 33 mesothelioma patients, in an effort to resolve what they call “conflicting data” on the two methods. SMRP and … Continue reading Diagnosing Pleural Mesothelioma with Lung Fluid: The Battle of the Biomarkers »

BAP1 May Be Valuable for Peritoneal Mesothelioma Prognosis

There is new evidence that the same genetic mutation that is common in people with pleural mesothelioma may be present in many cases of peritoneal mesothelioma, too. BAP1 is a tumor suppressing protein encoded by the BAP1 gene. People with a mutation in this gene are less likely to produce the protein and are more likely to develop certain kinds of cancer, including pleural mesothelioma. … Continue reading BAP1 May Be Valuable for Peritoneal Mesothelioma Prognosis »

Blood Test Could Aid in Mesothelioma Treatment Planning

Mesothelioma patients with elevated levels of a particular enzyme in their blood prior to the start of mesothelioma treatment may not live as long as those with lower levels. Afters years of mixed messages from researchers on this topic, scientists in China believe they have finally confirmed the value of the enzyme lactate dehydrogenase (LDH) as a prognostic factor in malignant pleural mesothelioma. LDH has been … Continue reading Blood Test Could Aid in Mesothelioma Treatment Planning »

Gene Test May Help Distinguish Pleural Mesothelioma from Lung Cancer

There is more evidence this week that the tumor suppressor gene known as BRCA1-associated protein 1 (BAP1) could help doctors distinguish pleural mesothelioma from other types of lung cancer – even cancers that commonly spread to the pleura. Pleural mesothelioma is unique among cancers in that it starts on the pleural membrane that surrounds the lungs. When other types of cancers metastasize to this region, … Continue reading Gene Test May Help Distinguish Pleural Mesothelioma from Lung Cancer »

International Team Identifies Potential New Mesothelioma Biomarker

A team of international researchers say they have identified a promising new biomarker for malignant pleural mesothelioma, a rare but deadly cancer caused by exposure to asbestos. A biomarker is a compound found in the tissue, blood or other body fluid that is produced in higher amounts when disease is present. In the case of a new report presented at the annual International Association for … Continue reading International Team Identifies Potential New Mesothelioma Biomarker »

New Clinical Trial Aims to Create Bioresource for Improved Mesothelioma Diagnosis

Malignant mesothelioma is not only one of the rarest and most difficult-to-treat cancers. It is also among the hardest to diagnose. The challenge of diagnosing the asbestos cancer can lead to delayed referral and late treatment and can limit mesothelioma patients’ access to clinical trials that might help them. In an effort to improve the diagnostic process for malignant mesothelioma, a group of researchers in … Continue reading New Clinical Trial Aims to Create Bioresource for Improved Mesothelioma Diagnosis »

Measuring Mesothelioma Treatment Response with Biomarkers

Malignant pleural mesothelioma is notoriously difficult to treat and doctors often have to try different treatment combinations to produce a response. But how can they know if a particular treatment strategy is working? A team of researchers in Pisa, Italy suggest that three key biomarkers may be the answer. Soluble mesothelin-related peptides (SMRP), plasma osteopontin (pOPM) and vimentin have all been studied as potential diagnostic … Continue reading Measuring Mesothelioma Treatment Response with Biomarkers »

New Marker for Mesothelioma Diagnosis and Follow-up

A protein most often used to measure the risk level in pregnancy may also offer a more reliable way to diagnose malignant pleural mesothelioma. Pleural mesothelioma is a highly aggressive cancer associated with asbestos exposure. Right now, there is no easy or definitive way to diagnose it and doctors have to rely on some combination of patient history, imaging studies, biopsy and blood tests. But a … Continue reading New Marker for Mesothelioma Diagnosis and Follow-up »

Get your free copy of
“Surviving Mesothelioma” Today!